Cellular therapy during COVID-19: Lessons learned and preparing for subsequent waves

An evidence-based triage plan for cellular therapy distribution is critical in the face of emerging constraints on healthcare resources. We evaluated the impact of treatment delays related to COVID-19 on patients scheduled to undergo hematopoietic cell transplantation (HCT) or chimeric antigen receptor T-cell (CAR-T) therapy at our center.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research